Therefore, the objective of this study was to estimate the cost-effectiveness of a combination treatment of BRAF plus MEK inhibitors with or without ICI treatments as a first-line adjuvant treatment for BRAF-mutant advanced melanoma from the US payer perspective. This evidence concerns the gene MAP2K7 and melanoma.